

6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma

September 26-29, 2018
Rotterdam, The Netherlands
Venue: De Doelen International Congress Centre

Pre-Symposium
Workshop
Sept 26, 2018

Presenting the latest scientific and clinical
advances in childhood, adolescent and young adult
Non-Hodgkin Lymphoma

Hosted By:

Mitchell S. Cairo, MD - Chair

Chief, Pediatric Hematology, Oncology and Stem Cell
Transplantation
Professor of Pediatrics, Medicine, Pathology, Microbiology
& Immunology and Cell Biology & Anatomy
Maria Fareri Children's Hospital
Westchester Medical Center (WMC)
New York Medical College

Auke Beishuizen, MD, PhD, - Co-Chair

Pediatric Oncologist/Hematologist
Erasmus MC – Sophia Children's Hospital
University Medical Center Rotterdam
And
Princess Máxima Center for Pediatric Oncology
Utrecht

For more information please go to <http://cayanhl.pcrf-kids.org>

or <http://www.cayanhl2018.com>



This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of New York Medical College and Pediatric Cancer Research Foundation. New York Medical College is accredited by the ACCME to provide continuing medical education for physicians.

New York Medical College designates this Live activity for a maximum of 23.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

SCHEDULE AT A GLANCE

Wednesday September 26 th	Thursday September 27 th	Friday September 28 th	Saturday September 29 th
Registration 2:00 PM – 9:00 PM	Registration 7:00 AM – 5:00 PM	Registration 7:00 AM – 5:00 PM	Registration 7:00 AM – 1:00 PM
NHL Wellness and Survivorship 6:00 PM – 8:00 PM	Opening Ceremony 8:00 AM – 8:15 AM Angelo Rosolen, MD Memorial Lecture 8:15 AM – 9:00 AM	Meet the Professors 7:30 AM – 8:15 AM	Meet the Professors 7:30 AM – 8:15 AM
Chair: Mitchell S. Cairo, MD, USA Co-Chair: Auke Beishuizen, MD, PhD, Netherlands International Scientific Committee & Faculty: Oussama Abla, MD, Canada Sarah Alexander, MD, Canada Carl Allen, MD, PhD, USA Mara Andres, MD, PhD, Spain Stephen M. Ansell, MD, PhD, USA Andishe Attarbaschi, MD, Austria Anthony N. Audino, MD, USA Matthew Barth, MD, USA Myriam Weyl Ben-Arush, MD, Israel Catherine Bollard, MD, USA Laurence Brugieres, MD, France Iliia Buhtoiarov, MD, USA Amos Burke, MD, UK Birgit Burkhardt, MD, PhD, Germany Guillermo Chantada, MD, PhD, Argentina Alan KS Chiang, MD, PhD, Hong Kong Monika Csoka, MD, Hungary Christine Damm-Welk, PhD, Germany Alan Davidson, MD, South Africa Ronit Elhasid, MD, Israel Alina Fedorova, MD, PhD, Russia Allyson Flower, MD, USA J. Kimble Frazer, MD, PhD, USA Paul Galardy, MD, USA Stanton Goldman, MD, USA Thomas Gross, MD, PhD, USA Michelle Hermiston, MD, PhD, USA Jessica Hochberg, MD, USA Scott Howard, MD, USA Ling Jin, MD, China Lukas Kenner, MD, Austria Wolfram Klapper, MD, Germany Claudete Esteves Klumb, MD, PhD, Brazil Ryoji Kobayashi, MD, PhD, Japan Yuhki Koga, MD, PhD, Japan M. Tezer Kutluk, MD, PhD, Turkey Megan Lim, MD, PhD, USA Michael Link, MD, USA Jan Loeffen, MD, PhD, Netherlands Eric Lowe, MD, USA Joseph Lubega, MD, MPH, Uganda Elizabeth Macintyre, MD, PhD, France Britta Maecker-Kolhoff, MD, Germany Christine Mauz-Körholz, MD, Germany Linda McAllister-Lucas, MD, PhD, USA Monika Metzger, MD, MSc, USA Friederike Meyer-Wentrup, MD, Netherlands Rodney Miles, MD, PhD, USA Veronique Minard-Colin, MD, PhD, France Tetsuya Mori, MD, PhD, Japan Lara Mussolin, PhD, Italy Ryotaro Nakamura, MD, USA Laura Pasqualucci, MD, USA	Plenary Session I B-Cell NHL 9:00 AM – 10:45 AM	Plenary Session V Anaplastic Large Cell Lymphoma 8:30 AM – 10:15 AM	Plenary Session IX Best Oral Abstracts in Childhood, Adolescent and Young Adult NHL 8:30 AM – 10:00 AM
	Break 10:45 AM – 11:00 AM	Break 10:15 AM – 10:30 AM	Break 10:00 AM – 10:15 AM
	Plenary Session II Adolescent and Young Adult NHL & HL 11:00 AM – 12:40 PM	Plenary Session VI T and NK NHL 10:30 AM – 12:15 PM	Plenary Session X Lymphoblastic Lymphoma 10:15 - 11:45 PM
	Lunch 12:45 – 1:45 PM	Lunch 12:15 – 1:45 PM	Awards Session 11:45 AM – 12:15 PM Closing Remarks 12:15 PM – 12:30 PM
	Plenary Session III Lymphoma Translational Biology (Dedicated in memory of Warren Sanger, PhD) 1:45 PM – 3:45 PM	Plenary Session VII Novel Therapeutics 1:15 PM – 1:30 PM	International Scientific Committee & Faculty: (Continued) Catherine Patte, MD, France Sherrie Perkins, MD, PhD, USA Rob Pieters, MD, Netherlands Marta Pillon, MD, Italy Leticia Quintanilla-Fend, MD, Germany Alfred Reiter, MD, Germany Stanley Riddell, MD, USA Leslie Robison, PhD, USA Lisa Giulino-Roth, MD, USA Elena V. Samochatova, MD, PhD, Russia John T. Sandlund, MD, USA Jennifer Sanmann, PhD, USA Florian Scherer, MD, Germany Margaret Shipp, MD, USA Bruce Shiramizu, MD, USA Reiner Siebert, MD, Germany Filippo Spreafico, MD, Italy Jaroslav Sterba MD, PhD, Czech Republic Jan Styczynski, MD, Poland X. F. Sun, MD, China Ritsuro Suzuki, MD, PhD, Japan Amanda Termuhlen, MD, USA Suzanne Turner, PhD, UK Anne Uyttebroeck, MD, PhD, Belgium Timur T.Valiev, MD, PhD, Russia Rein Willemze, MD, Netherlands Birte Wistinghausen, MD, USA Wilhelm Woessmann, MD, Germany Ana Xavier, MD, USA Jing Yang, MD, China Yonghong Zhang, MD, China Jozsef Zsiros, MD, Netherlands Christian Michel Zwaan, MD, PhD, Netherlands
	Break 3:45 PM – 4:00 PM	Break 3:15 PM – 3:30 PM	
	Plenary Session IV Lymphoma Immunology, BMT and Cell Therapy 4:00 PM – 5:45 PM	Plenary Session VIII Poster Discussion 3:00 PM – 6:00 PM	
	Welcome Reception 6:00 PM – 7:30 PM		

Wednesday, September 26, 2018

- 2:00 – 9:00 PM** **REGISTRATION**
- 6:00 – 8:00 PM** **Pre-Congress Workshop**
Childhood and Adolescent NHL Wellness and Survivorship
Jessica Hochberg, MD, USA & Leslie Robison, PhD, USA
- 6:00 – 6:30 PM** **CHILDHOOD AND ADOLESCENT NHL SURVIVORSHIP: THE CCSS PERSPECTIVE**
Leslie Robison, PhD, USA
- 6:30 – 6:45 PM** **CHILDHOOD AND ADOLESCENT NHL SURVIVORSHIP: THE BFM PERSPECTIVE**
Birgit Burkhardt, MD, PhD, Germany & Wilhelm Woessmann, MD, Germany
- 6:45 – 7:00 PM** **Burkitt Lymphoma (BL): Effect of Cyclophosphamide (CPM) on the Menarche and Fertility Rate in 113 Cameroonian patients.**
Peter B Hesseling¹, Glenn Afunchwi², Vera Njamshi³, Comfort Kimbi⁴, Patience Nfor⁵, Bernard Njodzeka⁶, Paul Wharin⁷, Francine Kouya⁸, Heather R Draper⁹
¹Department of Paediatrics and Child Health, Tygerberg Children's Hospital, University of Stellenbosch, South Africa, ²Banso Baptist Hospital, Northwest Region, Cameroon, ³Banso Baptist Hospital, Northwest Region, Cameroon, ⁴Mbingo Baptist Hospital, Northwest region, Cameroon, ⁵Mutengene Baptist Hospital, Southwest Region, Cameroon, ⁶Mutengene Baptist Hospital, Southwest Region, Cameroon, ⁷Beryl Thyer Memorial Africa Trust, Kettering, UK, ⁸Mbingo Baptist Hospital, Northwest Region, Cameroon; Heather R Draper MSc – ⁹Desmond Tutu TB Centre, Department of Paediatrics, University of Stellenbosch, South Africa
- 7:00 – 7:15 PM** **Influence of Methylenetetrahydrofolate Reductase Gene Polymorphisms on the High-dose Methotrexate Related Toxicity in Children Cancer Patients**
Suying Lu, MD^{1,2,3}, Xiaofei Sun, MD^{1,2,3*}, Zijun Zhen, MD, PhD^{1,2,3}, Jia Zhu, MD, PhD^{1,2,3}, Juan Wang, MD^{1,2,3}, Feifei Sun, MD, PhD^{1,2,3}, Junting Huang, MD, PhD^{1,2,3}.
¹State Key Laboratory of Oncology in South China, Guangzhou, Guangdong 510060, P. R. China; ²Collaborative Innovation Center of Cancer Medicine, Guangzhou, Guangdong 510060, P. R. China; ³Department of Pediatric Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, P. R. China
- 7:15 – 7:30 PM** **Long Term Follow Up of Pediatric Lymphoma Survivors upon Entry into a Wellness and Survivorship Program**
Jessica Hochberg, MD¹; Tara Giblin, PNP¹; Suzanne Braniecki, PhD¹, Rose Bartone, LCSW¹, Lauren Harrison, RN, MSN¹, Jackie Basso, RN, MSN, PNP¹, Allyson Flower, MD¹ and Mitchell Cairo, MD^{1,2,3,4,5}
¹Pediatrics, New York Medical College, Valhalla, NY; ²Medicine, ³Pathology, ⁴Microbiology and Immunology and ⁵Cell Biology and Anatomy, New York Medical College, Valhalla, NY
- 7:30 – 8:00 PM** **Panel Discussion – Drs. Hochberg, Robison, Burkhardt and Audience Participation**

Thursday, September 27, 2018

- 7:00 AM - 5:00 PM REGISTRATION**
- 8:00 – 8:10 AM **OPENING CEREMONY**
Mitchell S. Cairo, MD, Chair, USA
- 8:10 – 8:15 AM Auke Beishuizen, MD, PhD, Co-Chair, Netherlands
- 8:15 – 9:00 AM ANGELO ROSOLEN, MD, MEMORIAL LECTURE**
- 8:15 – 8:20 AM **INTRODUCTION**
Marta Pillon, MD, Italy, and Lara Mussolin, PhD, Italy - Co-Chairs
- 8:20 – 9:00 AM **PEDIATRIC NON-HODGKIN LYMPHOMA REVISITED WITH A VIEW FROM THE DISTANCE**
Alfred Reiter, MD, Germany
- 9:00 – 10:45 AM **PLENARY SESSION I - B-CELL NON-HODGKIN LYMPHOMA**
Moderators - Stanton Goldman, MD, USA & Sarah Alexander, MD, Canada
- 9:00 – 9:20 AM **PROMISING TARGETS IN B-CELL PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA**
Margaret Shipp, MD, USA
- 9:20 – 9:40 AM **DNA METHYLOME IN BURKITT LYMPHOMA**
Reiner Siebert, MD, Germany
- 9:40 – 10:00 AM **DIAGNOSIS AND TREATMENT OF RARE B-NHL VARIANTS IN CHILDREN AND ADOLESCENTS**
Andishe Attarbaschi, MD, Austria
- 10:00 – 10:10 AM **Reduced Burden of Oncologic Therapy in Children, Adolescents and Young Adults with Good Risk (GR) CD20+ Mature B-Cell Lymphoma**
Stan Goldman, MD¹ Matthew Barth, MD², Jessica Hochberg, MD³, Liana Klejmont, Pharm D³, Lauren Harrison, RN, MSN³, Quihi Shi, PhD³, Javier Oesterheld, MD⁴, Kenneth Heym, MD⁵, Sherrie Perkins, MD, PhD⁶, Rodney Miles, MD, PhD⁶, Bruce Shiramizu, MD⁷, and Mitchell Cairo, MD^{3,8,9,10,11,12}
¹*Pediatric Hematology/Oncology, Medical City Children's Hospital, Dallas, TX;* *Departments of* ²*Pediatrics, Roswell Park Cancer Institute, Buffalo, NY;* ³*Pediatrics, Medicine,* ⁹*Pathology,* ¹⁰*Microbiology & Immunology,* ¹¹*Cell Biology & Anatomy,* ¹²*Biostatistics, New York Medical College, Valhalla, NY;* ⁴*Levine Children's Hospital, Charlotte, NC;* ⁵*Cook Children's Medical Center,* ⁶*Pathology, University of Utah Health, Salt Lake City, UT;* ⁷*Tropical Medicine, Medical Microbiology & Pharmacology, University of Hawaii, Honolulu, HI.*
- 10:10 – 10:20 AM **Cancer Stem Cells in Paediatric B-Cell Non-Hodgkin Lymphoma are Detectable by Side Population Analysis and May Contribute to Therapy Resistance**
Sorcha Forde¹, Nina Prokoph¹, Liam C. Lee¹, Simon Bomken², G.A. Amos Burke^{3*}, and Suzanne D. Turner^{1*}

*¹Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK, ²Northern Institute for Cancer Research, Paul O'Gorman Building, Newcastle upon Tyne, UK, ³Department of Paediatric Oncology, Addenbrooke's Hospital, Cambridge, UK. *Equal contribution*

- 10:20 – 10:30 AM **UCH-L1 Bypasses mTOR to Promote Protein Biosynthesis and is Required for MYC Driven Lymphomagenesis in Mice**
Sajjad Hussain^{1*}, Tibor Bedekovics^{1*}, Qiuling Liu², Wenqian Hu², Sarah H. Johnson³, George Vasmatazis^{3,4}, Danielle G. May⁵, Kyle J. Roux^{5,6}, and Paul J. Galardy^{1,2,7}
¹Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN 55905, USA; ²Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, 55905; ³Center for Individualized Medicine-Biomarker Discover, Mayo Clinic, Rochester, MN, 55905; ⁴Department of Molecular Medicine, Mayo Clinic, Rochester, MN, 55905; ⁵Enabling Technology Group, Sanford Research, Sioux Falls, SD 57104, USA; ⁶Department of Pediatrics, Sanford School of Medicine, University of South Dakota, Sioux Falls, SD 57105, USA; ⁷Division of Pediatric Hematology-Oncology, Mayo Clinic, Rochester, MN 55905, USA
- 10:30 – 10:45 AM **Panel Discussion (moderators, plenary speakers, abstract speakers, audience) and Question & Answers**
- 10:45 – 11:00 AM **COFFEE BREAK**
- 11:00 – 12:40 PM **PLENARY SESSION II - ADOLESCENT AND YOUNG ADULT NON-HODGKIN AND HODGKIN LYMPHOMA**
Moderators - Monika Metzger, MD, MSc, USA & Christine Mauz-Körholz, MD, Germany
- 11:00 – 11:20 AM **PD-1 TARGETED THERAPY IN LYMPHOMAS**
Steve Ansell, MD, PhD, USA
- 11:20 – 11:40 AM **EPIDEMIOLOGY AND OUTCOME OF AYA WITH NHL AND HODGKIN LYMPHOMA**
Allyson Flower, MD, USA
- 11:40 – 12:00 PM **NOVEL TARGETED IMMUNOTHERAPY IN NEWLY DIAGNOSED CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH HODGKIN LYMPHOMA**
Jessica Hochberg, MD, USA
- 12:00 – 12:10 PM **Nonbiological Factors Affecting Outcomes in Adolescent and Young Adults with Lymphoma.**
Ana C. Xavier¹, Luciano J. Costa²
¹Division of Hematology/Oncology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, United States; ²Division of Hematology and Medical Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States.
- 12:10 – 12:20 PM **Clinical Features and Treatment Outcome of Children with Primary Mediastinal Large B-Cell Lymphoma in Taiwan**
Shih-Hsiang Chen¹, Chao-Ping Yang¹, on behalf of the Taiwan Pediatric Oncology Group (TPOG)

¹*Division of Hematology/Oncology, Department of Pediatrics, Linkou Chang Gung Memorial Hospital-, Chang Gung University College of Medicine, Taoyuan, Taiwan*

- 12:20 – 12:40 PM **Panel Discussion (moderators, plenary speakers, abstract speakers, audience) and Question & Answers**
- 12:40 - 1:45 PM **LUNCH**
- 1:45 – 3:45 PM **PLENARY SESSION III - LYMPHOMA TRANSLATIONAL BIOLOGY (DEDICATED IN MEMORY OF WARREN SANGER, PHD)**
Moderators - Paul Galardy, MD, USA & Elizabeth Macintyre, MD, PhD, France
- 1:45 – 1:50 PM **INTRODUCTION**
Jennifer N. Sanmann, PhD, USA
- 1:50 – 2:05 AM **THE T/MYELOID INTERFACE IN IMMATURE T LYMPHOID MALIGNANCIES"**
Elizabeth Macintyre, MD, PhD, France
- 2:05 – 2:25 PM **CIRCULATING TUMOR DNA (CTDNA) IN B-CELL LYMPHOMA**
Florian Scherer, MD, USA
- 2:25 – 2:45 PM **THE ROLE OF LIQUID BIOPSY IN NON-HODGKIN LYMPHOMAS OF CHILDHOOD**
Lara Mussolin, PhD, Italy
- 2:45 – 3:05 PM **MUTATIONAL LANDSCAPE OF PEDIATRIC-TYPE FOLLICULAR LYMPHOMA**
Leticia Quintanilla-Fend, MD, Germany
- 3:05 – 3:15 PM **Discovery of the First Zebrafish B Cell Lymphoblastic Lymphoma Model**
Chiara Borga PhD¹, Gilseung Park¹, Clay Foster PhD¹, Jessica Burroughs-Garcia PhD¹, Ameera Hasan MBBS¹, Rikin Shah MD¹, Megan Malone-Perez¹, Teresa Scordino MD², Rodney R. Miles MD, PhD³, James L. Regens PhD⁴, Geertruy te Kronnie PhD⁵, J. Kimble Frazer MD, PhD¹
¹*Pediatric Hematology-Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK,* ²*Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK,* ³*Pathology, University of Utah, and ARUP Institute for Clinical & Experimental Pathology, Salt Lake City, UT,* ⁴*Center for Intelligence and National Security, University of Oklahoma, Norman, OK,* ⁵*Department of Women's and Children's Health, University of Padua, Padua, Italy*
- 3:15 – 3:25 PM **IG-MYC-Positive Leukemia and Lymphoma with Precursor B-Cell Phenotype are Genetically and Epigenetically Distinct from Burkitt Lymphomas**
Cristina López^{1,2#}, Rabea Wagener^{1,2#}, Kortine Kleinheinz^{3,4}, Julia Bausinger¹, Sietse M. Aukema², Inga Nagel^{2,5}, Umut H.Toprak^{3,4}, Julian Seufert^{3,4,6}, Janine Altmüller⁷, Holger Thiele⁸, Christof Schneider⁹, Julia Kolarova^{1,2}, Jeongbin Park^{3,10}, Daniel Hübschmann^{3,4}, Eva M. Murga Penas², Hans G. Drexler¹¹, Andishe Attarbaschi¹², Randi Hovland¹³, Eigil Kjeldsen¹⁴, Michael Kneba¹⁵, Udo Kontny¹⁶, Laurence de Leval¹⁷, Peter Nürnberg⁷, Ilske Oschlies¹⁸, David Oscier¹⁹, Brigitte Schlegelberger²⁰, Stephan Stilgenbauer⁹, Wilhelm Wössmann²¹, Matthias Schlesner⁶, Birgit Burkhardt²², Wolfram Klapper¹⁸, Elaine S. Jaffe²³, Ralf Küppers²⁴, Reiner Siebert^{1,2,*}

¹Institute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, Germany, ²Institute of Human Genetics, Christian-Albrechts University Kiel & University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany, ³German Cancer Research Center (DKFZ), Division of Theoretical Bioinformatics, Heidelberg, Germany, ⁴Institute of Pharmacy and Molecular Biotechnology and Bioquant, University of Heidelberg, Heidelberg, Germany, ⁵Institute of Pharmacology, Christian-Albrechts University, Kiel, Germany, ⁶German Cancer Research Center (DKFZ), Bioinformatics and Omics Data Analytics, Heidelberg, Germany; ⁷Cologne Center for Genomics, Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany, ⁸Cologne Center for Genomics, University of Cologne, Cologne, Germany, ⁹Department of Internal Medicine III, University of Ulm, Ulm, Germany, ¹⁰Faculty of Biosciences, Heidelberg University, Heidelberg, Germany, ¹¹Leibniz-Institute DSMZ- German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany, ¹²Department of Pediatric Hematology and Oncology, St Anna Children's Hospital, Medical University of Vienna, Austria, ¹³Department for Medical Genetics, Haukeland University Hospital, Bergen, Norway, ¹⁴Cancercytogenetics Section, Hemodiagnostic Laboratory, Department of Haematology, Cancer and Inflammation Center, Aarhus University Hospital, Aarhus C, Denmark, ¹⁵Department of Hematology, University Hospital Schleswig-Holstein, Kiel, Germany, ¹⁶Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany, ¹ Institute of Pathology, Lausanne University Hospital, Lausanne, Switzerland, ¹⁸Hematopathology Section, Christian-Albrechts-University, Kiel, Germany, ¹⁹ Royal Bournemouth and Christchurch NHS Foundation Trust, Bournemouth, UK, ²⁰ Department of Human Genetics, Hannover Medical School, Hannover, Germany, ²¹Department of Pediatric Hematology and Oncology, Justus-Liebig University, Gießen, and NHL-BFM Study Center, Germany, ²²Department of Pediatric Hematology and Oncology and NHL-BFM study center, University Hospital Münster, Münster, Germany, ²³Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, 10 Center Drive, Bethesda, USA, ²⁴Institute of Cell Biology (Cancer Research), University of Duisburg-Essen, Medical School, Essen, Germany. #shared first authorship

3:25 – 3:35 PM

Mutational Spectrum of Relapse in Pediatric and Adolescent Patients with T-LBL

Tasneem Khanam¹, Charlotte Rüter¹, Christoph Bartenhagen^{2,5}, Jochen Seggewiß³, Heidi Herbrüggen¹, Stephanie Müller¹, Christian Wünsch², Ilse Oschlies⁴, Wolfram Klapper⁴, Martin Dugas², Sarah Sandmann², Birgit Burkhardt¹

¹Paediatric Hematology and Oncology, University Hospital Muenster, Germany,

²Institute of Medical Informatics, Muenster University, ³Institute of Human genetics, Muenster University, ⁴ Department of Pathology, Hematopathology Section, University Hospital Schleswig-Holstein, Kiel, Germany, ⁵Department of Experimental Pediatric Oncology, University of Cologne

3:35– 3:50PM

Panel Discussion (moderators, plenary speakers, abstract speakers, audience) and Question & Answers

3:50 – 4:00 PM

COFFEE BREAK

4:00 – 5:45 PM

PLENARY SESSION IV - LYMPHOMA IMMUNOLOGY, BMT AND CELL THERAPY

Moderators – Wilhelm Woessmann, MD, Germany & Mitchell S. Cairo, MD, USA

- 4:00 – 4:20 PM **HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RELAPSED/REFRACTORY NHL**
Wilhelm Woessmann, MD, Germany
- 4:20 – 4:40 PM **NEW ADVANCES ON CAR-T-CELL THERAPY IN B-NHL**
Stanley Riddell, MD, USA
- 4:40 – 5:00 PM **CMV-CD19 BI-SPECIFIC CAR T CELLS AND POST-INFUSION CMV VACCINE STRATEGIES**
Ryotaro Nakamura, MD, USA
- 5:00 – 5:10 PM **Safety and Efficacy of Myeloablative Conditioning Autologous Stem Cell Transplantation, Targeted Immunotherapy, and Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in Children, Adolescents, and Young Adults with Relapsed/Refractory Mature B-Cell Non Hodgkin Lymphoma**
A Gardenswartz, MD¹, B Mehta, MD¹, N El-Mallawany, MD¹, C van de Ven, MS¹, J Hochberg, MD¹, A Flower, MD¹, E Morris, RN, BSN¹, L Harrison, RN, MSN¹, J Basso, RN, MSN, CPNP¹, P Gerard², J Ayello, MS¹, L A Baxter-Lowe, PhD³, M S Cairo, MD^{1,4,5,6,7}.
¹Dept of Pediatrics, New York Medical College, Valhalla, NY, ² Dept of Radiology, New York Medical College, Valhalla, NY, ³Dept of Pathology, Children's Hospital Los Angeles, CA, ⁴Dept of Medicine, New York Medical College, Valhalla, NY, ⁵ Dept of Pathology, New York Medical College, Valhalla, NY, ⁶ Dept of Microbiology and Immunology, and ⁷ Dept of Cell Biology and Anatomy, New York Medical College, Valhalla, NY
- 5:10 – 5:20 PM **Early Response Data for Pediatric Patients with Non-Hodgkin Lymphoma Treated with CD19 Chimeric Antigen Receptor (CAR) T-Cells**
Julie Rivers¹, Colleen Annesley¹, Corinne Summers¹, Olivia Finney², Michael Pulsipher³, Alan Wayne³, Julie Park¹, Michael Jensen², Rebecca Gardner¹
¹Seattle Children's Hospital, Seattle, WA, USA; ²Seattle Children's Research Institute, Seattle, WA, USA; ³Children's Hospital of Los Angeles, Los Angeles, CA, USA
- 5:20 – 5:30 PM **Role of HSCT in Children and Adolescents with Refractory or Relapsed NHL**
Birgit Burkhardt¹, Marta Pillon², Mary Taj³, Nathalie Garnier⁴, Veronique Minard⁵, Volkan Hazar⁶, Karin Mellgren⁷, Tomoo Osumi⁸, Alina Fedorova⁹, Natalia Myakova¹⁰, Jaime Verdu-Amoros¹¹, Mara Andres¹², Edita Kabickova¹³, Andishe Attarbaschi¹⁴, Alan Chiang¹⁵, Eva Bubanska¹⁶, Svetlana Donska¹⁷, Lisa Lyngsie Hjalgrim¹⁸, Jacek Wachowiak¹⁹, Anna Pieczonka¹⁹, Anne Uyttebroeck²⁰, Jan Loeffen²¹, Jochen Buechner²², Felix Niggli²³, Julia Palma²⁴, Amos Burke²⁵, Auke Beishuizen²¹, Kristin Koeppen¹, Heidi Herbrueggen¹, Wilhelm Woessmann²⁶, Martin Zimmermann²⁷, Adriana Balduzzi²⁸
¹University Hospital Muenster, Department of Pediatric Hematology, Oncology and BMT, Münster, Germany, ²University-Hospital of Padua, Department of Child and Woman Health, Oncology Hematology Division, Padua, Italy, ³Royal Marsden Hospital, Department of Paediatric Oncology, Surrey, United Kingdom, ⁴Hospices Civils de Lyon, Institute of Pediatric Hematology and Oncology, Lyon cedex, France, ⁵Gustave Roussy Cancer Campus, Department of Pediatric Oncology, Villejuif, France, ⁶Medical Park Göztepe Hospital, Departments of Pediatric Hematology and Oncology and BMT Unit, İstanbul, Turkey, ⁷Sahlgrenska University Hospital, Department of Pediatric Oncology and Hematology, The Queen Silvia Children's Hospital, Gothenburg, Sweden, ⁸Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan, ⁹Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Clinical Research Department, Minsk, Belarus, ¹⁰Pediatric Hematology and Oncology,

Federal Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia, ¹¹University Hospital Valencia, Department of Pediatric Hematology and Oncology, Valencia, Spain, ¹²University Hospital Le Fe, Department of Pediatric Oncology, Valencia, Spain, ¹³Charles University & University Hospital Motol, Department of Paediatric Haematology and Oncology, Prague, Czech Republic, ¹⁴St. Anna Children's Hospital, Medical University of Vienna, Department of Pediatric Hematology and Oncology, Vienna, Austria, ¹⁵Department of Pediatrics & Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, ¹⁶Slovak Health University and Children's Faculty Hospital, Clinic of Pediatric Oncology and Hematology, Banská Bystrica, Slovakia, ¹⁷National Ukrainian Children`s Hospital "Ochmatdyt", Center of Pediatric Oncohematology and BMT, Kiev, Ukraine, ¹⁸Department of Paediatrics and Adolescent Medicine, Copenhagen, Denmark, ¹⁹Poznan University of Medical Sciences, Department of Pediatric Oncology, Hematology and Transplantology, Poznan, Poland, ²⁰University Hospital Gasthuisberg, Department of Paediatric Haematology and Oncology, Leuven, Belgium, ²¹Erasmus Medical Center Rotterdam, Sophia Children's Hospital, Department of Pediatric Oncology and Hematology, Rotterdam, The Netherlands, ²²Oslo University Hospital, Department of Pediatric Hematology and Oncology, Oslo, Norway, ²³University Children`s Hospital Zurich, Department of Pediatric Oncology, Zürich, Switzerland, ²⁴University of Chile – Faculty of Medicine, Hospital Luis Calvo Mackenna, Department of Pediatrics – Bone Marrow Transplantation Unit, Santiago, Chile, ²⁵Cambridge University Hospitals NHS Foundation Trust, Department of Paediatric Haematology and Oncology and Palliative Care, Addenbrooke`s Hospital, Cambridge, United Kingdom, ²⁶Justus-Liebig-University, Department of Pediatric Hematology and Oncology, Giessen, Germany, ²⁷Hannover Medical School, Department of Pediatric Hematology and Oncology, Hannover, Germany, ²⁸Clinica Pediatrica Università degli Studi di Milano Bicocca, Ospedale San Gerardo, University of Milano-Bicocca, San Gerardo Hospital, Monza, Italy

5:30 – 5:45 PM **Panel Discussion (moderators, plenary speakers, abstract speakers, audience) and Question & Answers**

6:00 – 7:30 PM **WELCOME RECEPTION (ALL REGISTRANTS/FACULTY/STAFF/SIGNIFICANT OTHERS)**
LOCATION: ROTTERDAM CITY HALL

Friday, September 28, 2018

7:00 AM - 5:00 PM **REGISTRATION**

7:30 – 8:30 AM **Meet the Professors (Choose One Session)**

Session 1 **MOLECULAR GENETICS IN NON-HODGKIN LYMPHOMA FOR THE CLINICIAN**
Wolfram Klapper, MD, Germany

Session 2 **DIAGNOSIS AND TREATMENT OF MATURE B-CELL LYMPHOMA IN CHILDREN: CHALLENGING CASES**
Catherine Patte, MD, France

Session 3	NEW PEDIATRIC INTERNATIONAL STAGING AND RESPONSE CRITERIA FOR CHILDHOOD AND ADOLESCENT NHL John Sandlund, MD, USA
Session 4	HISTIOCYTOSIS SYNDROMES: NEW DIRECTIONS AND CHALLENGING CASES Carl Allen, MD, PhD, USA
Session 5	NEW PATHOLOGICAL ENTITIES IN NHL: THE REVISED WHO CLASSIFICATION Sherrie Perkins, MD, PhD, USA
8:30 – 10:15 AM	PLENARY SESSION V - ANAPLASTIC LARGE CELL LYMPHOMA Moderators - Eric Lowe, MD, USA & Suzanne Turner, PhD, UK
8:30 – 8:50 AM	PRIMARY CUTANEOUS ALCL AND OTHER CUTANEOUS LYMPHOMAS IN CHILDREN AND ADOLESCENTS Rein Willemze, MD, Netherlands
8:50 – 9:10 AM	NOVEL PATHWAYS OF ONCOGENESIS IN ALCL Megan Lim, MD, PhD, USA
9:10 – 9:30 AM	ORIGINS AND PATHOGENESIS IN ALCL Suzanne Turner, PhD, UK
9:30 – 9:40 AM	Comprehensive Characterization of Plasma-Derived Exosomes in Anaplastic Large Cell Lymphoma of Childhood Federica Lovisa ^{1,2} , Enrico Gaffo ¹ , Stefania Bortoluzzi ³ , Anna Garbin ^{1,2} , Piero Di Battista ^{1,2} , Elisa Carraro ¹ , Piero Faruggia ⁴ , Alessandra Sala ⁵ , Matilde Piglione ⁶ , Luciana Vinti ⁷ , Emanuele S.G. D'Amore ⁸ , Giuseppe Basso ^{1,2} , Marta Pillon ¹ , Lara Mussolin ^{1,2} ¹ <i>Clinic of Paediatric Onco-Haematology, Department of Women's and Children's Health, University of Padova,</i> ² <i>Istituto di Ricerca Pediatrica Città della Speranza, Padova,</i> ³ <i>Department of Molecular Medicine, University of Padova, Padova,</i> ⁴ <i>A.R.N.A.S. Ospedali Civico Di Cristina e Benfratelli, Palermo,</i> ⁵ <i>Department of Paediatrics, San Gerardo Hospital, University of Milano-Bicocca, Fondazione MBBM, Monza,</i> ⁶ <i>Department of Paediatric Onco-Haematology, Children's Hospital Regina Margherita, Torino,</i> ⁷ <i>Department of Paediatric Onco-Haematology, IRCCS Ospedale Bambino Gesù, Roma,</i> ⁸ <i>Department of Pathological Anatomy, San Bortolo Hospital, Vicenza, Italy</i>
9:40 – 9:50 AM	Examining the Function of PDGFRB in Anaplastic Large Cell Lymphoma Ines Garces de los Fayos Alonso ^{1,2,3} , Michael Kothmayer ^{2,3} , Michaela Schleder ² , Oliver Pusch ⁴ , Simone Tangermann ³ , Sabine Lagger ³ and Lukas Kenner ^{1,2,3} ¹ <i>Ludwig Boltzmann Institute for Cancer Research (LBI-CR), 1090 Vienna,</i> ² <i>Clinical Institute of Pathology, Medical University of Vienna, 1090 Vienna,</i> ³ <i>Unit of Laboratory Animal Pathology, Veterinary University of Vienna, 1210 Vienna,</i> ⁴ <i>Center for Anatomy and Cell Biology, Medical University of Vienna, 1090 Vienna, Austria</i>
9:50 – 10:00 AM	The Anaplastic Large Cell Lymphoma (ALCL)-Associated Nucleophosmin-Anaplastic Lymphoma Kinase (NPM-ALK) Directs Expression of the Nuclear Protein Brahma Related Gene 1 (BRG1) Driving Cell Survival Stephen P. Ducray ^{1,6} , Gavin D. Garland ¹ , Tu Truong ¹ , Nina Prokoph ^{1,6} , Kojo S. J.

Elenitoba-Johnson^{2,6}, Megan S. Lim^{2,6}, Olaf Merkel^{3,6}, Lukas Kenner^{3,4,5,6}, Andrew Bannister⁷ and Suzanne D. Turner^{1,6}

¹*Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK CB20QQ*, ²*Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA*, ³*Medical University of Vienna, Vienna, Austria*, ⁴*University of Veterinary Medicine Vienna, Vienna, Austria*, ⁵*Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria*, ⁶*European Research Initiative for ALK-Related Malignancies (www.erialcl.net)*, ⁷*Gurdon Institute, Cambridge, UK.*

- 10:00 – 10:15 AM** **Panel Discussion (moderators, plenary speakers, abstract speakers, audience) and Question & Answers**
- 10:15 – 10:30 AM** **COFFEE BREAK**
- 10:30 – 12:15 PM** **PLENARY SESSION VI - T AND NK NON-HODGKIN LYMPHOMA**
Moderators - Ana Xavier, MD, USA & Ritsuro Suzuki, MD, PhD, Japan
- 10:30 – 10:50 AM** **DIAGNOSIS AND OUTCOME OF EXTRANODAL NK/T-CELL LYMPHOMA IN CHILDREN AND ADOLESCENTS: THE JAPAN EXPERIENCE**
Ritsuro Suzuki, MD, PhD, Japan
- 10:50 - 11:10 AM** **NOVEL TREATMENT AND OUTCOME OF EXTRANODAL NK AND T-CELL LYMPHOMA: THE BEIJING EXPERIENCE**
Jing Yang, MD, China
- 11:10 – 11:30 AM** **AUTOLOGOUS VS. ALLOGENEIC HSCT FOR PATIENTS WITH T-CELL AND NK NON-HODGKIN LYMPHOMA**
Amanda Termuhlen, MD, USA
- 11:30 – 11:40 AM** **Hydroa Vacciniforme–Like Lymphoproliferative Disorder: A Systematic Review**
Liliana Vasquez, M.D.¹; Iván Maza, M.D.¹; Brady Beltrán, M.D.², María Quiñonez, M.D.³
¹*Pediatric Oncology Division, Rebagliati Hospital; Lima*, ²*Clinical Oncology Department, Rebagliati Hospital; Lima*, ³*Pathology Department, Rebagliati Hospital; Lima, Peru.*
- 11:40 – 11:50 AM** **Subcutaneous Panniculitis-Like T-Cell Lymphoma (SPTCL)-Rare Non-Hodgkin Lymphoma in Children with Heterogenous Clinical Course. Polish Centres Experience**
Lucyna Maciejka-Kemblowska¹, Marta Kozłowska¹, Jadwiga Maldyk², Marcelina Osak¹, Grazyna Wrobel³, Anna Wakulinska⁴, Tomasz Ociepa⁵, Andrzej Koltan⁶, Ewa Dudkiewicz⁷, Ninela Irga-Jaworska¹, Bernarda Kazanowska³, Elżbieta Adamkiewicz-Drożyńska¹
¹*Department of Pediatrics, Hematology and Oncology, Medical University of Gdansk*, ²*Department of Developmental Pathology, Medical University of Warsaw*, ³*Department of Clinic of Pediatric Oncology, Hematology and Bone Marrow Transplantation, Wrocław Medical University*, ⁴*Department of Pediatric Oncology, The Children's Memorial Health Institute, Warsaw*, ⁵*Department of Pediatrics, Hematology and Oncology, Pomorski Medical University in Szczecin*, ⁶*Department of Pediatric Hematology and Oncology, Nicolaus Copernicus University, Collegium Medicum Bydgoszcz*, ⁷*Clinic of Pediatric Hematology and Oncology, Medical University of Lublin, Poland.*

11:50 – 12:00 PM	<p>Successful Outcome with Reduced-Intensity Condition Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Anaplastic Large-Cell Lymphoma</p> <p>Reiji Fukano^{1,2}, Naoto Fujita³, Tetsuya Mori⁴, Ryoji Kobayashi⁵, Tetsuo Mitsui⁶, Koji Kato⁷, Ritsuro Suzuki⁸, Junji Suzumiya⁸, Takahiro Fukuda⁹, Motohiro Shindo¹⁰, Nobuo Maseki¹¹, Tatsu Shimoyama¹², Keiko Okada¹³, Masami Inoue¹⁴, Jiro Inagaki¹, Yoshiko Hashii¹⁵, Atsushi Sato¹⁶, Ken Tabuchi¹⁷</p> <p>¹Department of Pediatrics, National Kyushu Cancer Center, ² Department of Pediatrics, Yamaguchi University Graduate School of Medicine, ³Department of Pediatrics, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, ⁴Department of pediatrics, St. Marianna University School of Medicine, ⁵Department of Pediatrics, Sapporo Hokuyu Hospital, ⁶Department of Pediatrics, Yamagata University Hospital, ⁷Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, ⁸Department of Oncology/Hematology, Shimane University Hospital, ⁹Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, ¹⁰Division of Gastroenterology and Hematology/Oncology Department of Medicine, Asahikawa Medical University, ¹¹Department of Hematology, Saitama Cancer Center, ¹²Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, ¹³Department of Pediatric Hematology/Oncology, Osaka City General Hospital, ¹⁴Department of Hematology/Oncology, Osaka Women's and Children's Hospital, ¹⁵Department of Pediatrics, Osaka University Graduate School of Medicine; ¹⁶Hematology and Oncology, Miyagi Children's Hospital, ¹⁷Division of Pediatrics, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital</p>
12:00 – 12:15 PM	<p>Panel Discussion (moderators, plenary speakers, abstract speakers, audience) and Question & Answers</p>
12:15 – 1:15 PM	<p>LUNCH</p>
1:15 – 3:30 PM	<p>PLENARY SESSION VII - NOVEL THERAPEUTICS Moderators - Veronique Minard-Colin, MD, PhD, France & Matthew Barth, MD, USA</p>
1:15 – 1:35 PM	<p>NEW TARGETED THERAPY IN NHL Mitchell S. Cairo, MD, USA</p>
1:35 – 1:55 PM	<p>NOVEL TARGETS AND OUTCOME IN ALCL Eric Lowe, MD, USA</p>
1:55 – 2:15 PM	<p>NOVEL AGENTS IN DEVELOPMENT IN CHILDREN AND ADOLESCENTS WITH HEMATOLOGICAL MALIGNANCIES WITHIN THE EMA C.M. Zwaan, MD, PhD, Netherlands</p>
2:15 – 2:25 PM	<p>Ruxolitinib Significantly Enhances in vitro Apoptosis in Hodgkin Lymphoma (HL) and Primary Mediastinal B-Cell Lymphoma (PMBL) and Survival in a Lymphoma Xenograft Murine Mouse: an AYA Therapeutic Opportunity Selena R. Levine¹, Tishi Shah¹, Jessica Hochberg¹, Janet Ayello¹, Erin Morris¹, Carmella van de Ven¹ and Mitchell S. Cairo^{1,2,3,4,5}</p>

Departments of Pediatrics¹, Cell Biology&Anatomy², Medicine³, Pathology⁴, Microbiology and Immunology⁵, New York Medical College, Valhalla, NY 10595.

2:25 – 2:35 PM

Ibrutinib Significantly Inhibited Bruton's Tyrosine Kinase (BTK) Phosphorylation, *In-Vitro* Proliferation and Enhanced Overall Survival in a Preclinical Burkitt Lymphoma (BL) Model

Gaurav Nayyar^{1*}, Yaya Chu^{1*}, Tishi Shah¹, Matthew Barth³, Rodney R. Miles⁴, Janet Ayello¹, Erin Morris¹, Lauren Harrison¹, Carmella van de Ven¹, Paul Galardy⁵, Stanton C. Goldman⁶, Megan S. Lim⁷, Michelle Hermiston⁸, Linda M. McAllister-Lucas⁹, Lisa Giulino-Roth¹⁰, Sherrie L. Perkins⁴, and Mitchell S. Cairo^{1,2,11,12,13}

¹Department of Pediatrics, ²Cell Biology & Anatomy, ¹¹Microbiology & Immunology, ¹²Medicine, ¹³Pathology, New York Medical College, Valhalla, NY, Valhalla, ³Pediatrics, University of Buffalo, Buffalo, NY, ⁴Pathology, University of Utah, Salt Lake City, UT, ⁵Pediatrics, Mayo Clinic, Rochester, MN, ⁶Pediatric Hematology/Oncology, Medical City Children's Hospital, Dallas, TX, ⁷Pathology and Laboratory Medicine, University of Pennsylvania, PA, ⁸Pediatrics, University of California, San Francisco, CA, ⁹Pediatrics, University of Pittsburgh, Pittsburgh, PA, ¹⁰Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, *Authors contributed equally to this work.

2:35 – 2:45 PM

Omipalisib (GSK458), a Dual Pan-PI3K/mTOR Inhibitor, Exhibits *in vitro* and *in vivo* Activity in Chemotherapy-Sensitive and –Resistant Models of Burkitt Lymphoma

Thomas Ippolito¹, Greg Tang¹, Cory Mavis², Juan Gu², Francisco Hernandez-Illizaliturri², Matthew J. Barth¹

¹Department of Pediatrics, University at Buffalo, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA; ²Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

2:45 – 3:15 PM

Panel Discussion (moderators, plenary speakers, abstract speakers, audience) and Question & Answers

3:15 – 3:30 PM

COFFEE BREAK

3:30 – 6:00 PM

PLENARY SESSION VIII - POSTER DISCUSSION SESSION (ABSTRACTS 1 - 30)

Moderators - Michael Link, MD, USA & Megan Lim, MD, PhD, USA

Staging and Response Evaluation in CAYA NHL –
Discussant: John T. Sandlund, MD, USA

Can FDG-PET Replace Biopsy for the Evaluation of Residual Tumor in Mature B Cell NHL?

Hany Abdel Rahman, MD¹, Samah Semary, MD², Gehad Taha, MD³, Naglaa El Kenaie MD⁴, Iman Zaki MD⁵, Walid Omar MD⁶, Nouran Yasser MSc⁷, Ola Ahmed MSc⁷

¹Department of pediatric oncology National Cancer Institute Cairo University and Children Cancer Hospital, ²Department of Pediatric Oncology, Faculty of Medicine Beni Sweif University and Children Cancer Hospital, ³Department of Surgery, Helwan University and Children Cancer Hospital, ⁴Department of Pathology, National Cancer Institute Cairo University and Children Cancer Hospital, ⁵Department of Radio-diagnosis National Cancer Institute Cairo University, and Children Cancer Hospital, ⁶Department of

Nuclear Medicine National Cancer Institute Cairo University and Children Cancer Hospital, ⁷Department of Clinical Research, Children Cancer Hospital, Egypt.

Application of the International Pediatric Non-Hodgkin Lymphoma Staging System (IPNHLS) to Pediatric Patients Newly Diagnosed with B-Cell Non-Hodgkin's Lymphoma (B-NHL) Enrolled in the AIEOP LNH-97 Protocol

Daniela Onofrillo¹, Silvia Pascale¹, Elisa Carraro², Davide Massano², Lara Mussolin²⁻³, Rosamaria Mura⁴, Luciana Vinti⁵, Salvatore Buffardi⁶, Piero Farruggia⁷, Simone Cesaro⁸, Alessandra Tolva⁹, Patrizia Bertolini¹⁰, Matilde Piglione¹¹, Annalisa Tondo¹², Nicola Santoro¹³, Alberto Garaventa¹⁴, Luca Lo Nigro¹⁵, Alessandra Sala¹⁶, Marta Pillon²
¹Pediatric Hemato-Oncology Unit, Hematology Dpt, Hospital of Pescara, ²Clinic of Pediatric Hemato-Oncology, Hospital-University of Padova, Padova, ³Istituto di Ricerca Pediatrica, Fondazione Città della Speranza, Padova, ⁴Pediatric Hematology-Oncology, Ospedale Pediatrico Microcitemico, Cagliari, ⁵Pediatric Hemato-Oncology Dpt, IRCCS, Bambino-Gesù Children's Hospital, Roma, ⁶Pediatric Hemato-Oncology Unit, Pausilipon Hospital, Napoli, ⁷Department of Paediatric Haemato-Oncology, ARNAS Ospedali Civico, G Di Cristina, Palermo, ⁸Pediatric Hemato-Oncology Unit, G.B. Rossi Hospital, Verona, ⁹Pediatric Hematology / Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia
¹⁰Pediatric Hematology Oncology, Azienda Ospedaliera Universitaria di Parma, Parma, ¹¹Hemato-Oncology Unit, Regina Margherita Hospital, University of Torino, Torino, ¹²Pediatric Hemato-Oncology Dpt, Meyer University-Hospital, Firenze, ¹³Division of Pediatric Hematology Oncology, Department of Pediatrics, Bari, ¹⁴Hemato-Oncology Unit, Gaslini Children's Hospital, Genova, ¹⁵Center of Paediatric Haematology, Azienda Policlinico-OVE, Catania, ¹⁶Department of Paediatrics, Ospedale San Gerardo, University of Milano-Bicocca, Fondazione MBBM, Monza, Italy

Whole-body MRI with Diffusion Weighted Imaging with Body Suppression (DWIBS) in the Follow up of Paediatric Non-Hodgkin Lymphoma: a Comparison with 18F-FDG PET-CT

Tondo A.¹, Olianti C.², Azzali A.¹, Cuzzubbo D.¹, Sanfilippo C.¹, Carra F.¹, Favre C.¹, De Filippi C.³, Perrone AL³.

¹Department of Hematology and Oncology, Anna Meyer Children's University Hospital, Florence, ²Nuclear Medicine Unit, Careggi University Hospital, Florence, ³Pediatric Radiology, University of Florence, Anna Meyer Children's University Hospital, Florence, Italy

A Genomic Classification Model Enables Risk Stratification of Paediatric Endemic Burkitt Lymphoma

Peixun Zhou¹, Amir Enshaei¹, Alexander M Newman¹, Kondwani Banda², George Chagaluka², Irvin Lampert³, Susan Van Noorden⁴, Amy Erhorn¹, Amy Barnard¹, Rachel E Crossland¹, Sarah Wilkinson¹, Sirintra Nakjang¹, Anthony V Moorman¹, Katrina Wood⁵, Despina Televantou⁵, Peter Carey⁶, Simon Bomken^{1,7}, Chris M Bacon^{1,5}, Simon Bailey^{1,7}, Elizabeth Molyneux², Vikki Rand¹

¹Wolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, Newcastle upon Tyne, UK., ²College of Medicine, Queen Elizabeth Central Hospital Department of Paediatrics, Blantyre, Malawi, ³West Middlesex University Hospital, Department of Histopathology, Isleworth, UK, ⁴Imperial College London, Department of Histopathology, London, UK, ⁵Department of Cellular Pathology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK, ⁶Department of

Haematology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK, ⁷Department of Paediatric and Adolescent Haematology and Oncology, The Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK

Change to OEPA/COPAC and PET-CT Based Treatment Strategy from Former ABVD/COPP for Treating Pediatric Hodgkins Lymphoma- Lessons Learnt from Chandigarh, India

Jaikumar Ramamoorthy, Deepak Bansal, Sonali Mohapatra, Amita Trehan
Pediatric Hematology Oncology Unit, Department of Pediatrics, Advanced Pediatric Centre, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India

Biology of Anaplastic Large Cell Lymphoma –
Discussant: Megan Lim, MD, PhD, USA

Investigating the Functional Impact of Single Nucleotide Variants in Anaplastic Large Cell Lymphoma

Hugo Larose¹, Shahid Mian², Edem Nuglozeh², Feroze M.S. Fazaludeen³, Ahmed Elmouna², Ibraheem Ashankyty², Ming-Qing Du¹, Gerald Hoefler⁴, Sarka Pospisilova⁵, Wilhelm Woessmann⁶, Christine Damm-Welk⁶, Alina Fedorova⁷, Laurence Lamant⁸, Michaela Schleder⁹, Olaf Merkel⁹, Lukas Kenner^{9,10,11} and Suzanne D. Turner¹

¹Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK CB20QQ, ²Molecular Diagnostics and Personalised Therapeutics Unit, Colleges of Medicine and Applied Medical Sciences, University of Ha'il, Ha'il, Saudi Arabia, ³Department of Neurobiology, University of Eastern Finland, Finland, ⁴Medical University of Graz, Graz, Austria, ⁵CEITEC, Brno, Czech Republic, ⁶Justus-Liebig University, Giessen, Germany, ⁷Belarusian Centre for Paediatric Oncology, Hematology and Immunology, Minsk, Belarus, ⁸Institut Universitaire du Cancer Toulouse, Oncopole et Université Paul-Sabatier, Toulouse, France, ⁹Medical University of Vienna, Vienna, Austria, ¹⁰University of Veterinary Medicine Vienna, Vienna, Austria, ¹¹Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria

Quantification of Minimal Disseminated Disease in Npm-Alk-Positive Anaplastic Large Cell Lymphoma: Validation Cohort and Method

C. Damm-Welk¹, M. Zimmermann¹, A. Attarbaschi², N. Kutscher¹, J. Schieferstein¹, I. Oschlies³, W. Klapper³, W. Woessmann¹

¹NHL-BFM study center, Dept. of Pediatric Hematology and Oncology, Giessen, Germany, ²Dept. of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, ³Institute of Pathology, Hematopathology Section and Lymph Node Registry, Kiel, Germany

NPM-ALK Expression Levels are Associated to Different miRNA Profiles in Paediatric Anaplastic Large Cell Lymphoma

Anna Garbin^{1,2}, Federica Lovisa^{1,2}, Katia Basso³, Antony B. Holmes³, Elisa Carraro¹, Marco Pizzi⁴, Alberto Garaventa⁵, Annalisa Tondo⁶, Rossella Mura⁷, Salvatore Buffardi⁸, Giuseppe Basso^{1,2}, Emanuele S.G. D'Amore⁹, Marta Pillon¹, Lara Mussolin^{1,2}

¹Clinic of Pediatric Onco-Hematology, Department of Women's and Children's Health, University of Padova, Italy; ²Istituto di Ricerca Pediatrica Città della Speranza, Padova, Italy; ³Institute for Cancer Genetics, Columbia University, New York, NY USA; ⁴Surgical Pathology and Cytopathology Unit, Department of Medicine, University of Padova, Italy; ⁵Department of Hematology-Oncology, Istituto Giannina Gaslini, Genova, Italy; ⁶AOU Meyer Children Hospital, Firenze, Italy; ⁷Pediatric Hematology-Oncology, Ospedale Pediatrico Microcitemico, Cagliari, Italy; ⁸Santobono-Pausilipon Hospital, Napoli, Italy; ⁹Department of Pathological Anatomy, San Bortolo Hospital, Vicenza, Italy

The AP-1 –BATF and –BATF3 Module: Divergent Roles in Tumour Growth, Invasion and Angiogenesis in Anaplastic Large Cell Lymphoma

Liang HC^{1,7}, Prutsch N¹, Gurnhofer E¹, Timelthaler G², Eferl R², Tangermann S³, Horvath J⁴, Stoiber D^{4,5}, Mathas S^{6,7}, Kenner L^{1,3,4}, Merkel O^{1,7*}

¹Clinical Institute for Pathology, Medical University of Vienna, Vienna, Austria; ²Institute of Cancer Research, Medical University of Vienna, Vienna, Austria; ³Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Vienna, Austria; ⁴Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria; ⁵Institute of Pharmacology, Medical University of Vienna, Vienna, Austria; ⁶Hematology, Oncology and Tumour Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany; ⁷European Research Initiative on ALK-related malignancies (ERIA), Cambridge, UK. * Correspondence: olaf.merkel@meduniwien.ac.at

Large B-Cell Lymphomas with ALK-Rearrangement Display a Different Genetic and Epigenetic Profile than Diffuse Large B-Cell Lymphoma

Wagener R^{1,#}, Schnaudt C^{1,#}, Kleinheinz K^{2,3}, Ammerpohl O.¹, Altmüller J⁴, Thiele H⁵, Kolarova J.¹, Agirre X⁶, Nürnberg P⁴, Brousset P^{7,8}, Klapper W⁹, Laurent C.⁷, Martin-Subero I¹⁰, Prósper F⁶, Woessmann W¹¹, Xerri L¹², Schlesner M^{2,13}, Siebert R¹

¹Institute of Human Genetics, University Ulm and Ulm University Medical Center, Ulm, Germany, ²German Cancer Research Center DKFZ, Division of Theoretical Bioinformatics, Heidelberg, Germany, ³Institute of Pharmacy and Molecular Biotechnology and Bioquant, University of Heidelberg, Heidelberg, Germany, ⁴Cologne Center for Genomics, Center for Molecular Medicine Cologne CMMC, University of Cologne, Cologne, Germany, ⁵Cologne Center for Genomics, University of Cologne, Cologne, Germany, ⁶Area de Oncología, Centro de Investigación Médica Aplicada, Ciberonc, Universidad de Navarra, Pamplona, Spain, ⁷Department of Pathology, Institut Universitaire du Cancer Toulouse Oncopole, CHU de Toulouse, Toulouse, France, ⁸Laboratoire d'excellence Labex TOUCAN, Toulouse, France, ⁹Hematopathology Section, Christian-Albrechts-University, Kiel, Germany, ¹⁰Institut D'investigacions Biomediques August Pi I Sunyer, Center for Biomedical Diagnosis, Barcelona, Spain, ¹¹Pediatric Hematology and Oncology, Justus-Liebig-University, Gießen, Germany, ¹²Department of Bio-Pathology, Institut Paoli-Calmettes and Aix-Marseille Univ, Marseille, France, ¹³German Cancer Research Center DKFZ, Bioinformatics and Omics Data Analytics, Heidelberg, Germany. # shared first-authorship

Bone Marrow and Cell Therapy in Relapsed/Refractory NHL – Discussant:
Wilhelm Woessmann, MD, Germany

Therapy and Outcome of Children and Adolescents with Progressive or Relapsed Lymphoblastic Lymphoma: Updated NHL-BFM Experience

Stephanie Müller¹, Heidrun Herbrüggen¹, Andishe Attarbaschi², Edita Kabickova³, Felix Niggli⁴, Ilske Oschlies⁵, Wolfram Klapper⁵, Martin Zimmermann⁶, Wilhelm Woessmann⁷
Birgit Burkhardt¹

¹Pediatric Hematology and Oncology, University Hospital Muenster, Germany; ²Pediatric Hematology and Oncology, St. Anna Children's Hospital, Vienna, Austria; ³Pediatric Hematology and Oncology, University Hospital Motol, Prague, Czech Republic; ⁴Pediatric Hematology and Oncology, University Hospital, Zürich, Switzerland, ⁵Department of Pathology, Hematopathology Section, University Hospital Schleswig-Holstein, Kiel, Germany; ⁶Pediatric Hematology and Oncology, Medical School Hannover, Hannover, Germany; ⁷Pediatric Hematology and Oncology, Justus-Liebig-University, Giessen, Germany

Beneficial Effect of aGVHD on Outcomes After Allogeneic Stem Cell Transplantation for Refractory LBL in Children

Tetsuo Mitsui¹, Naoto Fujita², Yuhki Koga³, Reiji Fukano⁴, Tomoo Osumi⁵, Makiko Mori⁶, Koji Kato⁷, Katsuyoshi Koh⁶, Yuri Okimoto⁸, Masami Inoue⁹, Yoshiko Hashii¹⁰, Atsushi Sato¹¹, Yoshiko Atsuta¹², Junji Suzumiya¹³, Ryoji Kobayashi¹⁴

¹Department of Pediatrics, Yamagata University Hospital, Yamagata, Japan; ²Department of Pediatrics, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima, Japan; ³Department of Pediatric Medicine for Hospital Collaboration, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; ⁴Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Ube, Japan; ⁵Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan; ⁶Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan; ⁷Department of Hematology and Oncology, Children's Medical Center, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan; ⁸Department of Hematology and Oncology, Chiba Children's Hospital, Chiba, Japan; ⁹Department of Hematology/Oncology, Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka, Japan; ¹⁰Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan; ¹¹Department of Hematology/Oncology, Miyagi Children's Hospital, Sendai, Japan; ¹²Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan; ¹³Innovative Cancer Center/Oncology-Hematology, Shimane University Hospital Cancer Center, Izumo, Japan; ¹⁴Department of Pediatrics, Sapporo Hokuyu Hospital, Sapporo, Japan

BEAM-Campath Conditioning Prior to Allogeneic Stem Cell Transplantation in First Remission in Two Cases of Hepatosplenic T Cell Lymphoma

Lane, J.P.¹, Lau, M.², Barge, D.³, Shenton, G.¹, Skinner, R.^{1,4}, James, B.², Wilkins, S.², Bomken, S.^{1,4}

¹Paediatric Oncology and Haematology, Great North Children's Hospital, Newcastle upon Tyne, UK; ²Children's and Adolescent Oncology and Haematology, Leeds General Infirmary, Leeds, UK; ³Department of Blood Sciences, Royal Victoria Infirmary, Newcastle upon Tyne, UK; ⁴Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK

Dissecting EBV-Specific T-cell Responses after Allogeneic EBV-Specific T-Cell Transfer for CNS PTLD

Britta Maecker-Kolhoff^{1,2}, Rebecca E. Schultze-Florey^{1,2}, Sabine Tischer^{2,3}, Leonie Kuhlmann⁴, Patrick Hundsdoerfer⁵, Arend Koch⁶, Sarina Ravens⁴, Lilia Goudeva³, Christian Schultze-Florey^{4,7}, Christian Koenecke^{4,7}, Rainer Blasczyk³, Ulrike Koehl^{2,8}, Hans-Gert Heuft³, Immo Prinz⁴, Britta Eiz-Vesper^{2,3}

¹Pediatric Hematology and Oncology, Hannover Medical School, Hannover, ²Integrated Research and Treatment Center Transplantation (IFB-Tx), Hannover Medical School, Hannover, ³Institute for Transfusion Medicine, Hannover Medical School, Hannover, ⁴Institute of Immunology, Hannover Medical School, Hannover, ⁵Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, and Berlin Institute of Health, Department of Pediatric Hematology and Oncology, ⁶Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, and Berlin Institute of Health, Department of Neuropathology, ⁷Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Hannover Medical School, Hannover, ⁸Institute of Cellular Therapeutics, Hannover Medical School, Hannover, Germany

2B8T2M, a Novel Fusion of ALT-803, an IL-15 Superagonist, with 4 Single-Chains of anti-CD20 Antibody Significantly Enhanced Expanded Natural Killer Cells Cytotoxicity against Rituximab Sensitive and Resistant Burkitt Lymphoma (BL)

Yaya Chu, PhD¹, Nang Kham Su, BS¹, Emily K. Jeng², Sarah Alter, PhD³, Peter R. Rhode, PhD³, Gaurav Nayyar¹, Mathew Barth, MD⁴, Dean A. Lee, MD/PhD⁵, Hing C. Wong, PhD², Mitchell S. Cairo MD^{1,6,7,8,9,10}

¹Pediatrics, New York Medical College, Valhalla, NY, ²HCW Biologics, Miramar, FL, ³Altor BioScience, Miramar, FL, ⁴Department of Pediatrics, State University of New York at Buffalo, Buffalo, NY, USA, ⁵Hem/Onc/BMT, Nationwide Children's Hospital, Columbus OH, ⁶Medicine, ⁷Medicine, ⁸Pathology, ⁹Microbiology and Immunology and ¹⁰Cell Biology and Anatomy, Maria Fareri Children's Hospital, New York Medical College, Valhalla, NY

Novel Therapeutics in CAYA B-NHL – Discussant:

Michael Link, MD, USA

Low Level of Cerebrospinal fluid (CSF) Rituximab (RTX) following Intravenous Rituximab in Children, Adolescents and Young Adults (CAYA) with de novo Mature B-cell Non-Hodgkin Lymphoma (B-NHL)

Matthew J. Barth^{1*}, Yaya Chu^{2*}, Stanton C. Goldman³, Jessica Hochberg², Javier Oesterheld⁴, Kenneth Heym⁵, Lauren Harrison², Harshini Mahanti², Allyson Flowers², Jackie Basso² and Mitchell S. Cairo^{2,6,7,8,9}.

¹Roswell Park Cancer Institute, Buffalo, NY; ³Department of Pediatric Hematology/Oncology, Medical City Children's Hospital, Dallas, TX and Texas Oncology, PA; ²Department of Pediatric Hematology/Oncology, New York Medical College, Valhalla, NY; ⁴Levine Children's Hospital, Charlotte, NC; ⁵Cook Children's Medical Center, Texas, ⁶Medicine, ⁷Pathology, ⁸Microbiology and Immunology and ⁹Cell Biology and Anatomy, Maria Fareri Children's Hospital, New York Medical College, Valhalla, NY *co-primary first authors

Synergistically Enhanced in-vitro Cytotoxicity and Overall Survival in NSG xenografts against Burkitt Lymphoma (BL) and Primary Mediastinal Large B cell Lymphoma (PMBL) by Polatuzumab Vedotin (hu- anti-CD79b-vc-MMAE, PV) alone or in combination with Obinutuzumab

Aradhana Awasthi, MPH, PhD¹, Dina Edani, MS¹, Janet Ayello, MS, MT(ASCP)¹, Christian Klein, Ph.D², and Mitchell S. Cairo, MD^{1,3,4,5,6}

Department of ¹Pediatrics, ³Medicine, ⁴Pathology, Microbiology & Immunology, ⁵Cell Biology & Anatomy, New York Medical College, Valhalla, NY, ⁶Department of Medicine, NY, USA, ²Roche Pharmaceutical Research & Early Development, Roche Innovation Center Zurich, Switzerland

Phase 2 Trial of Obinutuzumab, a Humanized, Glycoengineered Monoclonal CD20 Antibody, in Combination with Ifosfamide, Carboplatin and Etoposide for Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

Matthew J. Barth*¹, Jessica Hochberg*², Lauren Harrison², Stanton Goldman³, Allyson Flowers², Mitchell S. Cairo^{2,4,5,6,7}

¹Pediatric Hematology/Oncology, Roswell Park Comprehensive Cancer Center and University at Buffalo, Buffalo, NY; ²Pediatric Hematology/Oncology, New York Medical College, Valhalla, NY; ³Pediatric Hematology/Oncology, Medical City Children's Hospital, Dallas, TX; ⁴Pediatrics, ⁵Medicine, ⁶Pathology, ⁷Microbiology and Immunology and Cell Biology and Anatomy, New York Medical College, Valhalla, NY * Co-first authors

Comparing Survival Rates Between Pediatric and Adult Regimens of Treatment for B-Cell Non-Hodgkin Lymphoma in Adolescents and Young Adults

Rios L.¹, Castro D.², Vasquez L.¹, Geronimo J.¹

¹Pediatric Oncology Unit, Hospital Edgardo Rebagliati Martins, ²Medical Oncology Service, Hospital Edgardo Rebagliati Martins, Lima Peru.

Outcomes of Burkitt Lymphomas in Children with a Risk-Stratified Approach at a Tertiary Cancer Center in India

Gaurav Narula*, Anand KC, Maya Prasad, Sneha Shah, Shripad D Banavali

Department of Medical Oncology, Tata Memorial Center, Mumbai, Maharashtra, India

**Biology of CAYA Non-Hodgkin Lymphoma –
Discussant: Wolfram Klapper, MD, Germany**

Molecular Profiling of Adolescent Hepatosplenic T-cell Lymphoma Reveals Somatic Mutations in EZH2, KRAS, and STAG2

Troy A. McEachron^{1,2}, Leonard S. Sender^{3,4}, Keri B. Zabokrtsky^{3,5}, Aaron F. Sassoon³, David W. Craig^{1,2}, John D. Carpten^{1,2}, Van T. Huynh³, Zarko Manojlovic³, Ivan I. Kirov³
¹Keck School of Medicine, University of Southern California, Los Angeles, ²University of Southern California Norris Comprehensive Cancer Center, Los Angeles, ³Children's Hospital of Orange County, Orange, ⁴NantKwest, Culver City, ⁵University of California Irvine, Orange, California, United States of America

**Peripheral T Cell Lymphoma in Children with Nijmegen Breakage Syndrome (NBS)
Report of 4 Cases**

B.Dembowska-Baginska¹, A.Wakulinska¹, M.Stypinska¹, W.Grajkowska², K.Chrzanowska³
Department of Oncology¹, Department of Pathology², Department of Genetics³, The
Children's Memorial Health Institute, Warsaw, Poland

**Recurrently Mutated Pathway-Derived Network in Pediatric-Type Follicular
Lymphoma**

Federica Lovisa^{1,2}, Andrea Binatti³, Alessandro Coppe³, Simona Primerano^{1,2}, Elisa
Carraro¹, Marta Pillon¹, Marco Pizzi⁴, Salvatore Buffardi⁵, Fulvio Porta⁶, Piero Faruggia⁷,
Raffaella De Santis⁸, Giuseppe Basso^{1,2}, Emanuele SG D'Amore⁹, Stefania Bortoluzzi³ &
Lara Mussolin^{1,2}

¹Clinic of Pediatric Onco-Hematology, Department of Women's and Children's Health,
University of Padova, ²Istituto di Ricerca Pediatrica Città della Speranza, Padova,
³Department of Molecular Medicine, University of Padova, Padova, ⁴Surgical Pathology
and Cytopathology Unit, Department of Medicine, University of Padova, ⁵Santobono-
Pausilipon Hospital, Napoli, ⁶Children's Hospital, Spedali Civili, Brescia, ⁷A.R.N.A.S.
Ospedali Civico Di Cristina e Benfratelli, Palermo, ⁸IRCCS Casa Sollievo della Sofferenza,
San Giovanni Rotondo, Foggia, ⁹Department of Pathological Anatomy, San Bortolo
Hospital, Vicenza, Italy

**Investigation of FOXO1 Mutations in Paediatric Endemic and Sporadic Burkitt
Lymphoma**

Peixun Zhou¹, Alexander M Newman¹, Filbert Adlar¹, Casey Broadbent¹, Alex E Blain¹,
Amber Whitehead¹, Amy Hall¹, George Chagaluka², Elizabeth Molyneux², Simon Bailey¹,
Chris M Bacon^{1,3}, Simon Bomken^{1,4}, Vikki Rand¹

¹Wolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research,
Newcastle upon Tyne, UK, ²College of Medicine, Queen Elizabeth Central Hospital
Department of Paediatrics, Blantyre, Malawi, ³Department of Cellular Pathology,
Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK,
⁴Department of Paediatric and Adolescent Haematology and Oncology, The Great North
Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle
upon Tyne, UK

Targeted Panel for Pediatric T-LBL

Charlotte Rüter¹, Tasneem Khanam¹, Christoph Bartenhagen², Jochen Seggewiß³, Heidi
Herbrüggen¹, Stephanie Müller¹, Christian Wünsch⁴, Ilske Oschlies⁵, Wolfram Klapper⁵,
Martin Dugas⁴, Sarah Sandmann⁴, Birgit Burkhardt¹

¹Pediatric Hematology and Oncology, University Hospital Muenster, ²Department of
Experimental Pediatric Oncology, University Hospital Cologne, ³Institute of Human
Genetics, Muenster University, ⁴Institute of Medical Informatics, Muenster University,
⁵Department of Pathology, Hematopathology Section, University Hospital Schleswig-
Holstein, Kiel, Germany

International CAYA Non-Hodgkin Lymphoma –
Discussant: Thomas Gross, MD, USA

Retrospective Analysis of Clinical Features and Treatment Outcomes of Children with Anaplastic Large Cell Lymphoma: A Single Institutional Experience

¹Mahreen A, ¹Wali RM.

¹Department of Pediatric Oncology. Shaukat Khanum Cancer Hospital and Research Center, Lahore, Pakistan

Clinical Features and Outcomes of Pediatric Hodgkin Lymphoma in Asia

Michi Kamei¹, Yuhki Koga², Shih-Hsiang Chen³, Chao-Ping Yang³, Allen Eng Juh Yeoh⁴, Hany Ariffin⁵, Reiji Fukano⁶, Masahiro Sekimizu⁷, Shosuke Sunami⁸, Junichi Ueyama⁹, Tetsuo Mitsui¹⁰, Takeshi Mori¹¹, Tomoo Osumi¹², Kentaro Ohki¹³, Fumiko Tanaka¹⁴, Naoto Fujita¹⁵, Tetsuya Mori¹⁶, Ryoji Kobayashi¹⁷

¹Department of Pediatrics and Neonatology, Nagoya City University Graduate School of Medical Sciences, Japan, ²Department of Pediatrics, Graduate School of Medical Sciences Kyushu University, Japan, ³Division of Hematology/Oncology, Department of Pediatrics, Chang Gung Memorial Hospital, Taiwan, ⁴National University Cancer Institute Singapore, Singapore, ⁵Department of Paediatrics University of Malaya Medical Centre, Malaysia, ⁶Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Japan, ⁷Department of Pediatrics, National Hospital Organization Nagoya Medical Center, Japan, ⁸Department of Pediatrics, Japanese Red Cross Narita Hospital, Japan, ⁹Department of Pediatrics, Tottori University Hospital, Japan, ¹⁰Department of Pediatrics, Yamagata University Hospital, Japan, ¹¹Children's Cancer Center, National Center for Child Health and Development, Japan, ¹²Children's Cancer Center, National Center for Child Health and Development, Japan, ¹³Department of Pediatric Hematology and Oncology Research, National Center for Child Health and Development, Japan, ¹⁴Department of Pediatrics, Saiseikai Yokohamashi Nanbu Hospital, Japan, ¹⁵Department of Pediatrics, Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital, Japan, ¹⁶Department of Pediatrics, St. Marianna University School of Medicine Hospital, Japan, ¹⁷Department of Pediatrics and Adolescence, Sapporo Hokuyu Hospital, Japan

The Clinical Features and Therapeutic Effect for the Treatment of T cell Lymphoblastic Lymphoma / Leukemia in Childhood and Adolescence: Results of a Single Center in China

¹Ling Jin, ¹Yonghong Zhang, ¹Jing Yang, ¹Yanlong Duan, ¹Shuang Huang, ¹Meng Zhang, ¹Chunjv Zhou, ²Zifen Gao, ³Xiaoge Zhou

¹Hematology Oncology Center, Beijing Children' Hospital, Capital Medical University, Beijing, ²Pathology, Medical School of Beijing University, Beijing, ³Pathology, Beijing Friendship Hospital, Capital Medical University, Beijing, China

Protocol B-NHL-BFM 95+/- Rituximab: 10-year Experience

T.Valiev, G.Mentkevich

Pediatric Oncology and Hematology Research Institute of N.N.Blokhin National Cancer Center of the Ministry of Health of Russian Federation, Moscow, Russia

Children are 6 times More Likely than Adults to Develop Post -Transplant Lymphoproliferative Disease (PTLD)

¹James Ford, DO, ¹Jennifer Sanmann, PhD, ²Kelly Erickson, MPH, ¹Martin Bast, ¹Wendy Grant, MD, ¹Valerie Shostrom, MS, ¹Alan Langnas, DO, ¹Timothy Greiner, MD, ¹Peter Coccia, MD.

¹University of Nebraska Medical Center, Omaha, Nebraska, ²Children's Hospital and Medical Center of Omaha, Omaha, Nebraska, USA

Saturday, September 29, 2018

7:00 AM – 1:00 PM REGISTRATION

7:30 – 8:15 AM MEET THE PROFESSORS (CHOOSE ONE SESSION)

Session 1 **MINIMAL DISSEMINATED DISEASE (MDD) AND MINIMAL RESIDUAL DISEASE (MRD) IN CHILDHOOD AND ADOLESCENT NHL**
Bruce Shiramizu, MD, USA

Session 2 **DIAGNOSIS AND TREATMENT OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE: CHALLENGING CASES**
Thomas Gross, MD, PhD, USA

Session 3 **DIAGNOSIS AND MANAGEMENT OF LYMPHOBLASTIC LYMPHOMA: CHALLENGING CASES**
Birgit Burkhardt, MD, PhD, Germany

Session 4 **DIAGNOSIS AND MANAGEMENT OF ALCL: CHALLENGING CASES**
Laurence Brugieres, MD, France

Session 5 **DIAGNOSIS AND MANAGEMENT OF PRIMARY MEDIASTINAL B-CELL LYMPHOMA: CHALLENGING CASES**
Lisa Giulino-Roth, MD, USA

8:30 – 10:00 AM PLENARY SESSION IX - BEST ORAL ABSTRACTS IN CHILDHOOD, ADOLESCENT AND YOUNG ADULT NON-HODGKIN LYMPHOMA
Moderators - Mitchell S. Cairo, MD, USA, & Auke Beishuizen, MD, PhD, Netherlands

8:30 – 8:45 AM Regulation of Cytokine Release and anti-Tumor Effect of anti-CD20 CAR Modified Expanded Natural Killer Cells by ALT-803, an Il-15 Superagonist
Yaya Chu, PhD¹, Nang Kham Su, BS¹, Carl Hamby, PhD², Emily K. Jeng³, Sarah Alter, PhD⁴, Mathew Barth, MD⁵, Hing C. Wong, PhD³, Dean A. Lee, MD/PhD⁶, Mitchell S. Cairo MD^{1,7,8,9,10,11}

¹Pediatrics, New York Medical College, Valhalla, NY, ²Microbiology and Immunology, New York Medical College, Valhalla, NY, USA, ³HCW Biologics, Miramar, FL, ⁴Altor BioScience, Miramar, FL, ⁵Department of Pediatrics, State University of New York at Buffalo, Buffalo, NY, USA, ⁶Hem/Onc/BMT, Nationwide Children's Hospital, Columbus OH, ⁷Medicine, ⁸Medicine, ⁹Pathology, ¹⁰Microbiology and Immunology and ¹¹Cell

Biology and Anatomy, Maria Fareri Children's Hospital, New York Medical College, Valhalla, NY

8:45 – 9:00 AM

IG-MYC-Rearranged Neoplasms with Precursor B-Cell Immunophenotype in Pediatric and Adolescent Patients

Heidi Herbrueggen¹, Jonas Rohde², Anja Moericke³, Andishe Attarbaschi⁴, Richard Ratei⁵, Monika Brueggemann⁶, Reiner Siebert⁷, Brigitte Schlegelberger⁸, Wolfram Klapper⁹, Martin Zimmermann¹⁰, Willi Woessmann¹¹, Birgit Burkhardt¹

¹*Pediatric Hematology and Oncology, University Hospital Muenster, Germany;* ²*General Pediatrics, University Hospital Muenster, Germany;* ³*Department of Pediatrics, University Medical Center Schleswig-Holstein, Kiel, Germany;* ⁴*Pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria;* ⁵*Helios Klinikum Bad Saarow, Department of Hematology, Oncology and Palliative Care, Bad Saarow, Germany;* ⁶*Department of Hematology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany;* ⁷*Institute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, Germany;* ⁸*Department of Human Genetics, Hannover Medical School, Hannover, Germany;* ⁹*Department of Pathology, Hematopathology Section, University Hospital Schleswig-Holstein, Kiel, Germany;* ¹⁰*Pediatric Hematology and Oncology, Medical School Hannover, Hannover, Germany,* ¹¹*Pediatric Hematology and Oncology, Justus Liebig University, Giessen, Germany*

9:00 – 9:15 AM

Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma

Jessica C. Hochberg, MD¹, Liana Klejmont, Pharm D¹, Lauren Harrison, RN, MSN¹, Allyson M. Flower, MD¹, Quihu Shi, PhD², Jaclyn Basso, RN, MSN, PNP¹ and Mitchell S. Cairo, MD^{1,3,4,5,6}

¹*Pediatrics, New York Medical College, Valhalla, NY;* ²*Statistics, New York Medical College, Valhalla, NY;* ³*Medicine,* ⁴*Pathology,* ⁵*Microbiology and Immunology,* ⁶*Cell Biology and Anatomy, New York Medical College, Valhalla, NY*

9:15 – 9:30 AM

NPM-ALK REGULATES IMMUNE ESCAPE THROUGH CD48 IN ALK+ ALCLS

Rui Wu¹, Elena Ivan¹, Delphine Rolland¹, Anagh Sahasrabudhe¹, Kojo S. Elenitoba-Johnson¹, Megan S. Lim^{1,2}

¹*Department of Pathology and Laboratory Medicine, University of Pennsylvania, PA;* ²*Department of Pathology, Children's Hospital of Philadelphia, Perelman School of Medicine at University of Pennsylvania*

9:30 – 9:45 AM

Biallelic Inactivation of TP53 is Associated with an Increased Risk of Relapse in Paediatric B-Cell Non-Hodgkin Lymphoma (B-NHL)

Alexander M Newman¹, Masood Zaka¹, Peixun Zhou¹, Amy Erhorn¹, Amy Barnard¹, Rachel E Crossland¹, Sarah Wilkinson¹, Amir Enshaei¹, Mary Taj², Katrina Wood³, Despina Televantou³, Suzanne D Turner⁴, Amos Burke⁵, Christine J Harrison¹, Simon Bomken^{1,6}, Chris M Bacon^{1,3}, Vikki Rand¹

¹*Wolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, Newcastle upon Tyne, UK,* ²*Department of Paediatric Oncology, Royal Marsden Hospital, Sutton, Surrey, UK,* ³*Department of Cellular Pathology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK,* ⁴*Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK,* ⁵*Department of Paediatric Haematology, Addenbrooke's Hospital, Cambridge University*

Hospitals NHS Foundation Trust, Cambridge, UK, ⁶Department of Paediatric and Adolescent Haematology and Oncology, The Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK

9:45 – 10:00 AM

Interim Positron Emission Tomography And Childhood Hodgkin International Prognostic Score Can Predict Survival Of Children With Hodgkin Lymphoma In Developing Countries

Reham Khedr¹, Sally Mahfouz¹, Hoda Fathy², Lobna Shalaby¹

¹*Pediatric Oncology Department, ²Nuclear Medicine Department, National Cancer Institute - Cairo University, Children Cancer Hospital, Egypt, 57357*

10:00 – 10:15 AM

COFFEE BREAK

10:15 - 11:45 AM

PLENARY SESSION X - LYMPHOBLASTIC LYMPHOMA

Moderators - Birgit Burkhardt, MD, PhD, Germany & Michelle Hermiston, MD, PhD, USA

10:15 – 10:35 AM

PROGNOSTIC GENETIC FACTORS IN CHILDHOOD AND ADOLESCENT T-LYMPHOBLASTIC LYMPHOMA

Birgit Burkhardt, MD, PhD, Germany

10:35 – 10:55 AM

DIAGNOSIS AND TREATMENT OF CHILDHOOD AND ADOLESCENT B-LYMPHOBLASTIC LYMPHOMA

Birte Wistinghausen, MD, USA

10:55 – 11:05 AM

Genomic Analysis of Early T-Cell Precursor Lymphoblastic Lymphoma

Xinjie Xu^{1,2}, Christian N Paxton¹, Robert J. Hayashi³, Sherrie L Perkins^{1,2}, Rodney R. Miles^{1,2}

¹*ARUP Laboratories, Salt Lake City, Utah, ²Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, ³Pediatric Hematology/Oncology, Washington University School of Medicine, St. Louis, MO, USA*

11:05 – 11:15 AM

Glucocorticoids Paradoxically Induce Steroid Resistance Through a STAT5-Mediated Survival Mechanism in T-Cell Acute Lymphoblastic Leukemia/Lymphoma

Lauren K. Meyer¹, Cristina Delgado-Martin¹, Benjamin J. Huang¹, Anica M. Wandler¹, Terzah M. Horton², David T. Teachey³, Kevin M. Shannon^{1*}, and Michelle L. Hermiston^{1*}

¹*University of California, San Francisco, CA, ²Baylor College of Medicine, Houston, TX, ³University of Pennsylvania, Philadelphia, PA, USA *K.M.S. and M.L.H. contributed equally to this study*

11:15 – 11:25 AM

Global Genetic Profiling of a Pediatric Series of T-Cell Lymphoblastic Lymphoma

¹Idoia Martin-Guerrero*, ²Joan Enric Ramis-Zaldivar*, ³Verónica Celis, ⁴Olga Balagué, ⁵Jaime Verdú, Julia Salmerón-Villalobos, Constantino Sábado, ⁸Marta Garrido, ⁹Blanca Gonzalez-Farré, ¹⁰Itziar Astigarraga, ¹¹Mara Andrés, ¹²Itziar Salaverria * These two authors contribute equally to the study

¹*Faculty of Science and Technology, UPV/EHU, Leioa, ²Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, ³Hospital Sant Joan de Déu, Esplugues de Llobregat, ⁴Hospital Clínic, Barcelona, ⁵Hospital Clínic, Valencia, ⁶Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, ⁷Hospital Vall d'Hebron, Barcelona, ⁸Hospital*

Vall d'Hebron, Barcelona, ⁹Hospital Clínic, Barcelona, ¹⁰Hospital de Cruces, Bilbao, ¹¹Hospital La Fe, Valencia, ¹²Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona Spain

11:25 – 11:45 AM **Panel Discussion (moderators, plenary speakers, abstract speakers, audience) and Question & Answers**

11:45 – 12:15 PM **AWARDS SESSION BEST ORAL ABSTRACT, BEST POSTER DISCUSSION ABSTRACT & BEST POSTER ABSTRACT**
Award Committee - Marta Pillon, MD, Italy; John T. Sandlund MD, USA; Ronit Elhasid, MD, Israel; Oussama Abla, MD, Canada; Friederike Meyer-Wentrup, MD, Netherlands

12:15 – 12:30 PM **CLOSING REMARKS**
Mitchell S. Cairo, MD, Chair, USA

ABSTRACT SUBMISSION—DEADLINE *May 7, 2018 by 5pm EST*

- a. **ABSTRACTS MUST BE RECEIVED BY *Monday, May 7, 2018, 5:00 PM EST*, TO BE CONSIDERED FOR PRESENTATION.**
- b. **ABSTRACTS MUST ADDRESS** SCIENTIFIC QUESTIONS PERTAINING TO CHILDHOOD, ADOLESCENT, OR YOUNG ADULT NON-HODGKIN LYMPHOMA or HODGKIN LYMPHOMA
- c. ABSTRACTS WILL BE PUBLISHED IN *BRITISH JOURNAL OF HAEMATOLOGY*
- d. ABSTRACTS ARE TO BE SUBMITTED VIA E-MAIL AS A **MICROSOFT WORD DOCUMENT ATTACHMENT TO NHL_SYMPOSIUM@NYMC.EDU.**
- e. TO PRESENT AN ABSTRACT, APPLICANT MUST BE REGISTERED TO ATTEND THE SYMPOSIUM
- f. THERE IS NO ABSTRACT SUBMISSION FEE
- g. YOU CAN REGISTER FOR THE SYMPOSIUM AT THE SAME TIME OF ABSTRACT SUBMISSION AT OUR WEBSITE (<http://cayanhl.pcrf-kids.org>)

FINANCIAL NEED AWARDS

- a. FINANCIAL NEED AWARD --REGISTRANTS FROM A LOW-RESOURCED COUNTRY WHO HAVE AN ABSTRACT ACCEPTED MAY APPLY FOR A MERIT AWARD (REGISTRATION FEE WAIVER). A LETTER BY E-MAIL DETAILING REASONS FOR FINANCIAL NEED MUST BE ATTACHED WITH THE ABSTRACT SUBMISSION. (LIMIT--10 FINANCIAL NEED AWARDS).

BEST ABSTRACT AWARDS

- a. BEST ORAL ABSTRACTS WILL BE SELECTED BY SCIENTIFIC MERIT FOR ORAL PRESENTATION IN EACH PLENARY SESSION OF THE MEETING. AN AWARD OF \$1000 (US) WILL BE MADE FOR THE BEST ORAL PRESENTATION AT THE MEETING.
- b. EIGHTEEN ABSTRACTS OF NOTEWORTHY SCIENTIFIC MERIT WILL BE SELECTED FOR A POSTER DISCUSSION SESSION AT THE MEETING. AN AWARD OF \$1000 (US) WILL BE MADE FOR THE BEST POSTER DISCUSSION PRESENTATION AT THE MEETING.
- c. ADDITIONALLY, OTHER ACCEPTED ABSTRACTS WILL BE PRESENTED IN THE GENERAL POSTER SESSION. AN AWARD OF \$1000 (US) WILL BE MADE FOR THE BEST POSTER IN THE GENERAL SESSION AT THE MEETING.

ABSTRACT FORMAT

- a. ABSTRACTS MUST BE SUBMITTED VIA E-MAIL AS A **MICROSOFT WORD DOCUMENT** ATTACHMENT; **ABSTRACT SHOULD NOT EXCEED 400 WORDS INCLUDING TITLE AND BODY** (AUTHORS' NAMES AND INSTITUTIONS ARE NOT COUNTED). (Limit to one figure or one table are also not counted).
- b. **USE 10 PT. TIMES FONT.**
- c. **ABSTRACT FORMAT IS AS FOLLOWS:**
 - TITLE (TITLE CASE)
 - AUTHORS, INSTITUTION, CITY, STATE OR PROVINCE, COUNTRY
 - BODY (USE THE FOLLOWING HEADINGS):
 - BACKGROUND
 - OBJECTIVES
 - DESIGN/METHODS
 - RESULTS
 - CONCLUSION

THE FOLLOWING INFORMATION MUST BE INCLUDED IN THE E-MAIL WITH EACH SUBMISSION:

- a. NAME OF CORRESPONDING AUTHOR
- b. DEPARTMENT/INSTITUTION, CITY, COUNTRY
- c. TELEPHONE NUMBER
- d. E-MAIL ADDRESS OF CORRESPONDING AUTHOR
- e. CATEGORY DESIRED (AUTHORS MUST INDICATE THE ONE SCIENTIFIC CATEGORY)

1. B-CELL NON-HODGKIN LYMPHOMA	7. NOVEL THERAPEUTICS
2. AYA NON-HODGKIN AND HODGKIN LYMPHOMA	8. LYMPHOBLASTIC LYMPHOMA
3. T AND NK NON-HODGKIN LYMPHOMA	9. RELAPSED/REFRACTORY NHL
4. LYMPHOMA IMMUNOLOGY, BMT & CELL THERAPY	10. LATE EFFECTS / SURVIVORSHIP OF NHL
5. ANAPLASTIC LARGE CELL LYMPHOMA	11. HODGKIN LYMPHOMA
6. LYMPHOMA TRANSLATIONAL BIOLOGY	12. NHL IN LOW RESOURCED COUNTRIES

- ABSTRACTS PERTINENT TO CHILDHOOD, ADOLESCENT AND YOUNG ADULT NON-HODGKIN AND HODGKIN LYMPHOMA THAT HAVE BEEN ACCEPTED/PRESENTED AT SCIENTIFIC MEETINGS WITHIN THE PAST 18 MONTHS ARE ALSO ACCEPTABLE FOR SUBMISSION TO THIS SYMPOSIUM.
- **QUESTIONS SHOULD BE ADDRESSED TO MIGUEL MUNIZ AT NHL_SYMPOSIUM@NYMC.EDU**
- **SUBMIT ABSTRACT BY E-MAIL TO: NHL_SYMPOSIUM@NYMC.EDU**
- **ABSTRACT REVIEW:**
 - a. ABSTRACTS WILL BE PEER-REVIEWED ACCORDING TO SCIENTIFIC CATEGORIES.
 - b. NOTIFICATION OF ACCEPTANCE OR REJECTION OF ABSTRACTS WILL BE MADE VIA E-MAIL ON OR AROUND June 11th, 2018.
 - c. THE DECISION OF THE REVIEWING COMMITTEES REGARDING THE ACCEPTANCE OF ABSTRACTS IS FINAL.

CME Information

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of New York Medical College and Pediatric Cancer Research Foundation. New York Medical College is accredited by the ACCME to provide continuing medical education for physicians.

New York Medical College designates this Live activity for a maximum of *24.25 AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

LOCATION: ROTTERDAM, THE NETHERLANDS

Rotterdam, a city known for its architecture, is a Dutch city situated in the west part of The Netherlands. A major logistic and economic center, Rotterdam is Europe's largest port city with a population of 633,000 and over 2.9 million inhabitants in its metropolitan area combined with The Hague. Rotterdam is a modern, thriving cosmopolitan city with a breathtaking skyline and a wealth of cultures and ethnicities.

VENUE: DE DOELEN INTERNATIONAL CONGRESS CENTRE

The Willem Burger Complex

De Doelen ICC is Rotterdam's central arena for the exchange of information and cultural events. De Doelen ICC is divided into 3 complexes each with its own entrance. De Doelen ICC has earned a national and international reputation for its state of the art venue. The 6th International Symposium is being held in the Willem Burger Complex.

REACHING ROTTERDAM:

Symposium attendees can reach Rotterdam by air and train. Amsterdam's Schiphol Airport (AMS) is located 37 miles north of Rotterdam. From Schiphol Airport travel to Rotterdam City Center Rail Station is by high speed rail service operated by NS Dutch Railways. The high speed train operates from Schiphol Airport to Rotterdam City Center Rail Station every 15 minutes and the journey takes 27 minutes. De Doelen ICC and recommended hotels are within walking distance from Rotterdam City Center Rail Station.

For travelers arriving from Germany, Italy, France, Spain and the United Kingdom flights are available to Rotterdam The Hague Airport (RTM). Rotterdam The Hague Airport is located 4 miles north of the city with taxi service available.

ACCOMMODATIONS/REGISTRATION:

RESERVE ONLINE at <http://cayanhl.pcrf-kids.org>

A limited number of favorable hotel rates for conference registrants are available at:

The Bilderberg Park Hotel; Easy Hotel Rotterdam City Centre; The Holiday Express Rotterdam; Marriott Rotterdam

All hotels are within walking distance of De Doelen ICC.

Hotel accommodations must be reserved by August 26, 2018 to assure availability of blocked rooms at conference rates.

NOTE: All recommended hotels are fully accessible for registrants with disabilities. In order to accommodate any special needs please specify when registering for the conference.

CONFERENCE REGISTRATION FEES INFORMATION *USD:

Registration	By August 15 th , 2018	After August 15 th , 2018
Physicians / Scientists	\$ 750.00 USD	\$ 900.00 USD
Allied Professional / In Training	\$ 450.00 USD	\$ 600.00 USD
Pharmaceutical Representative	\$ 1,000.00 USD	\$ 1,250.00 USD
CME Credit	\$ 25.00 USD	\$ 25.00 USD
US currency only		

REGISTER ONLINE: <http://cayanhl.pcrf-kids.org>

Refund Policy:

50% of registration is refundable by July 15th, 2018, thereafter there are no refunds.

Late and On-Site Registration (After July 15th, 2018):

Attendees who register after July 15th, 2018 will be charged the late/on-site registration fee. On-site registration will begin on local times list below in the first-floor lobby of the De Doelen International Congress Centre.

Meeting Cancellation Policy:

The Pediatric Cancer Research Foundation (PCRF), New York Medical College and Erasmus MC reserve the right to modify or cancel any or all activities associated with this meeting due to unforeseen circumstances. In the event that we have to unexpectedly cancel this meeting before July 15, 2018, 50% off the registration fee will be returned. If the conference is cancelled after July 15, 2018, there will be no refund.